Fundraising Fox
/Companies
Sign in

Enanta Pharmaceuticals

NASDAQ: ENTA

Founded 1995 · 146 employees on LinkedIn · 3 known investors

Find your way into Enanta Pharmaceuticals

Sign up to see every warm intro you have to Enanta Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Enanta Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).

Biotech

Founders & leadership

JRJay R. Luly
Jay R. LulyPresident, Director and Chief Executive Officer
YS
Yat Sun OrChief Scientific Officer
STScott T. Rottinghaus
Scott T. RottinghausChief Medical Officer
MP
Matthew P. KowalskyChief Legal Officer and Corporate Secretary
TLTara L. Kieffer
Tara L. KiefferChief Product Strategy OfficerTara L. Kieffer holds a B.A. in Molecular Biology from Colgate University and a Ph.D. in Immunology from Johns Hopkins University School of Medicine. She brings extensive pharmaceutical industry experience across drug discovery, development, clinical trials, regulatory affairs, and commercial operations, with particular expertise in infectious disease therapeutics and contributions to hepatitis C treatments.
BLBrendan Luu
Brendan LuuChief Business OfficerHe has over 15 years of experience in business development and drug partnerships, with expertise across oncology, neurology, immunology, virology, and cardiometabolic diseases.

Investors · 3

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · Not right? Tell us

AbbViereportedCambridge · $300K – $3M

How we know: the S-1 prospectus · Not right? Tell us

Funding

SEC filings, press & company announcements
  • Undisclosed amountpublic offeringOct 2025
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events
$235.7Mvaluation at IPOMar 2013 · $14.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Enanta Pharmaceuticals went on to found or lead other companies.

Jens EcksteinDirector Lead Discovery and Research ITFounded Palleon PharmaceuticalsAxel BolteBoard ObserverFounded Inozyme Pharma

Frequently asked questions

What does Enanta Pharmaceuticals do?
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).
Who are Enanta Pharmaceuticals's investors?
Enanta Pharmaceuticals's investors include Saints Capital, Sofinnova Ventures, AbbVie.